About this trial
The goal of this physiological study is to compare albumin catabolic rate measured by a stable isotope labeled amino acid in healthy volunteers and in patients with liver disease. At steady state synthesis and catabolism or degradation are equal.
The primary questions it aims to answer are:
* Is albumin catabolic rate lower in patients with liver disease? * Is albumin catabolic rate measured by stable isotopes in volunteers like historical controls measured by radio-iodinated albumin at the investigator's laboratory or elsewhere? Subjects will be given an oral dose of the deuterium labeled amino acid phenylalanine that will be incorporated by the liver in newly synthetized albumin molecules, and blood samples will be taken over 12 weeks to determine the catabolic rate of albumin.
Eligibility criteria
Qualifiers
males and females >= 40 years (to be more like the anticipated age of the liver patients)
good peripheral blood vessels
written informed consent
known compensated liver cirrhosis with radiological or endoscopic signs of portal hypertension, such as varices, splenomegaly, or shunts.
Disqualifiers
Planned surgical procedure within 3 months (due to possible blood loss i.e. loss of tracer)
Pregnancy at dosing
Phenylketonuria
Participating in other study with stable isotopes within 60 days.
Trial design
Treatments tested in this trial
- stable isotopes
Treatment groups
Sponsors and collaborators
Ake Norberg
Lead sponsor
Karolinska Institutet
Sponsor institution